The EU's Critical Medicines Act, a pivotal piece of legislation aimed at bolstering the bloc's pharmaceutical resilience, has emerged from the crucible of negotiations with a softened stance on stockpiling and a nuanced approach to public procurement. This compromise, reached after a year of deliberations, reflects the delicate balance between the European Parliament's ambitions and the member states' concerns over national sovereignty and economic interests.
One of the most contentious issues was the sharing of medicine reserves during crises. The Parliament, led by Tomislav Sokol, advocated for mandatory sharing of national reserves, a move that would have created a more unified and robust EU-wide stockpile. However, EU governments, wary of ceding control over their crisis preparedness, resisted this proposal. The final agreement, while not mandating sharing, commits countries to exchanging information on contingency stocks and coordinating stockpiling efforts, ensuring a more collaborative approach without compromising national autonomy.
The legislation also reforms public procurement rules for critical medicines, expanding the scope for joint purchasing. This mechanism is designed to empower smaller states in their negotiations with pharmaceutical companies. A key point of contention was the threshold for domestic manufacturing in public tenders. The Parliament proposed a 50% threshold, but the final text, while still favoring European production, adopts a scoring system that prioritizes suppliers with greater production capacity in Europe, providing a more flexible and industry-friendly approach.
The agreement also includes provisions for 'strategic projects' aimed at expanding pharmaceutical manufacturing capacity closer to the EU's borders. Negotiators agreed to expedite permitting procedures for these projects, recognizing the urgency of boosting local production. However, the scope of these projects was narrowed, reflecting the member states' desire to avoid complications in the bloc's long-term budget negotiations.
This deal marks a significant achievement for Health Commissioner Olivér Várhelyi, who has demonstrated a proactive approach to addressing the bloc's pharmaceutical vulnerabilities. By fast-tracking the legislation and bypassing a formal impact assessment, he has achieved an early political victory. However, the agreement still requires formal approval from member states and the European Parliament, a necessary step to ensure its full implementation.
In my opinion, the Critical Medicines Act, despite its compromises, represents a significant step towards a more resilient and self-sufficient European pharmaceutical sector. While it may not have achieved all the Parliament's initial ambitions, it strikes a balance that addresses the immediate needs of the bloc while respecting the sovereignty of member states. This agreement is a testament to the EU's ability to navigate complex negotiations and emerge with a cohesive and forward-looking strategy.
